JonesResearch analyst Sean Kim initiated coverage of EyePoint Pharmaceuticals with a Buy rating and $26 price target. EyePoint is an ophthalmic biopharmaceutical company with its lead asset EYP-1901 in development for the treatment of wet age-related macular degeneration, the analyst tells investors in a research note. The firm says EYP-1901 represents a potential first-in-class maintenance therapy utilizing EyePoint’s Durasert technology, which enables “consistent and highly targeted drug release” through six months or longer from a single intravitreal injection.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EYPT:
- EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy
- EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference
- Alimera Soars as it Snaps Up Rights for Yutiq from EyePoint Pharma
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments